

OFFICIAL

Atty Docket No. 015389-002920US

PTO FAX NO.: (703) 305-3014

FAX RECEIVED

ATTENTION: Examiner Yvonne Eyler
Group Art Unit 1642


JUN 11 1999

OFFICIAL COMMUNICATION GROUP 1600**FOR THE PERSONAL ATTENTION OF
EXAMINER YVONNE EYLER****CERTIFICATION OF FACSIMILE TRANSMISSION**

I hereby certify that the following **PRELIMINARY AMENDMENT** and **AMENDMENT TRANSMITTAL** in re Application of Thomas Cech et al., Serial No. 08/846,017, filed April 25, 1997, for NOVEL TELOMERASE, are being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Number of pages being transmitted, including this page: 5

Dated: June 10, 1999



Susan L. Baka

**PLEASE CONFIRM RECEIPT OF THIS PAPER BY
RETURN FACSIMILE AT (650) 326-2422**

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, CA 94111-3834
Telephone: (650) 326-2400
Fax: (650) 326-2422

Amendment

TOWNSEND and TOWNSEND and CREW LLP
 Two Embarcadero Center, 8th Floor
 San Francisco, California 94111-3834
 (650) 326-2400

Attorney Docket No. 15389-002920US

In re application of: Thomas R. Chech et al.

Application No.: 08/846,017

Filed: April 25, 1997

Group Art Unit: 1642

For: NOVEL TELOMERASE

THE ASSISTANT COMMISSIONER FOR PATENTS
Washington, D.C. 20231

I hereby certify that this correspondence is being sent by facsimile transmission to Examiner Yvonne Eyer at (703) 305-3014,
 of Art Unit 1642 of the United States Patent and Trademark Office

On June 10, 1999

TOWNSEND and TOWNSEND and CREW LLP

By: Susan L. Baka
 Susan L. Baka

Sir:

Transmitted herewith is an amendment in the above-identified application.

- [] Enclosed is a petition to extend time to respond.
- [] Small entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified statement previously submitted.
- [] A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed.

If any extension of time is needed, then this response should be considered a petition therefor.

The filing fee has been calculated as shown below:

	(Col. 1)	(Col. 2)	(Col. 3)	
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA
TOTAL	*25	MINUS	** 23	= 2
[] FIRST PRESENTATION OF MULTIPLE DEP. CLAIM				

SMALL ENTITY		OTHER THAN SMALL ENTITY	
RATE	ADDIT. FEE	RATE	ADDIT. FEE
x \$9.00 =		x \$18.00 =	\$36.00
x \$39.00 =		x \$78.00 =	\$78.00
+ \$130.00 =		+ \$260.00 =	
TOTAL ADDIT. FEE		TOTAL	\$114.00
OR		OR	

* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.

*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, then write "3" in this space. The "Highest Number Previously Paid For" (Total or Independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment or the number of claims originally filed.


No fee is due.

Please charge Deposit Account No. 20-1430 as follows:

Claims fee \$ 114.00
 Any additional fees associated with this paper or during the pendency of this application.

2 extra copies of this sheet are enclosed.

TOWNSEND and TOWNSEND and CREW LLP



 Randolph T. Apple Reg. No.: 36,429
 Attorneys for Applicant

I hereby certify that this correspondence is being sent by facsimile transmission to Examiner Yvonne Eyler at (703) 305-3014, of Art Unit 1642 of the United States Patent and Trademark Office

On June 10, 1999

TOWNSEND and TOWNSEND and CREW LLP

By: Susan J. Baker

PATENT
Attorney Docket No.: 15389-002920

#19/C

RECEIVED
JUN 10 1999
GROUP 1800

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Thomas R. Cech et al.

Application No.: 08/846,017

Filed: April 25, 1997

For: NOVEL TELOMERASE

Examiner: Yvonne Eyler

Art Unit: 1642

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to examination of the above-referenced application, please amend the claims as follows:

IN THE CLAIMS:

Please add the following new claims:

—27. A pharmaceutical composition comprising an antisense oligonucleotide that hybridizes to a polynucleotide having the sequence of SEQ. I.D. No.: 100 and a carrier.

28. A method of detecting a condition or disease characterized by expression of a telomerase protein subunit comprising contacting a biological sample from a patient and a detectably labeled antibody capable of specifically binding the polypeptide of claim 26.—

C1